Finance

Lists
500660:BOM
GlaxoSmithKline Pharmaceuticals Ltd
2 567,25 INR
+1,75%
(+44,25) 1D
16 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500660...
Open
2 527,25 INR
High
2 572,40 INR
Low
2 527,25 INR
Mkt. cap
434,57 მლრ.
Avg. vol.
5,03 ათ.
Volume
2,37 ათ.
Dividend
2,22%
Quarterly dividend
14,25 INR
Ex-dividend date
29 მაი. 2026
P/E ratio
40,72
52-wk high
3 121,10 INR
52-wk low
2 088,00 INR
EPS
63,05 INR
Shares outstanding
169,41 მლნ.
No. of employees
3 ათ.
Open
2 527,25 INR
High
2 572,40 INR
Low
2 527,25 INR
Mkt. cap
434,57 მლრ.
Avg. vol.
5,03 ათ.
Volume
2,37 ათ.
Dividend
2,22%
Quarterly dividend
14,25 INR
Ex-dividend date
29 მაი. 2026
P/E ratio
40,72
52-wk high
3 121,10 INR
52-wk low
2 088,00 INR
EPS
63,05 INR
Shares outstanding
169,41 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
22 წუთის წინ
Phase 3 Lung Trials Could Be A Big Test For Insmed (INSM)
Law360
Law360
·
1 საათის წინ
Nasdaq Sued Over Delisting Of Social Media Co.
Kalkine Media
Kalkine Media
·
31 წუთის წინ
Royal Bank of Canada Launches Bearish PLUS Securities on S&P 500 with Maturity in November 2027
Yahoo Finance
Yahoo Finance
·
56 წუთის წინ
Dow (DOW) Stock Could Look Reasonable After a 43% Gain
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3,1 ათ.
Founded13 ნოე. 1924
Headquarters-
SectorPharmaceutical industry
Websiteindia-pharma.gsk.com
Last report
3 აგვ. 2026
Fiscal period
Q1 2027
14,00 INR / 13,90 INR
+0,72%beat
Revenue / Est. (INR)
9,38 მლრდ. / 9,11 მლრდ.
+3,00%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
9,80 მლრდ.
10,41 მლრდ.
9,95 მლრდ.
9,38 მლრდ.
Cost of goods sold
3,56 მლრდ.
3,64 მლრდ.
3,69 მლრდ.
3,28 მლრდ.
Cost of revenue
3,56 მლრდ.
3,64 მლრდ.
3,69 მლრდ.
3,28 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,38 მლრდ.
1,52 მლრდ.
2,95 მლრდ.
1,59 მლრდ.
Operating expense
3,06 მლრდ.
3,26 მლრდ.
2,84 მლრდ.
3,31 მლრდ.
Total operating expenses
6,62 მლრდ.
6,90 მლრდ.
6,53 მლრდ.
6,59 მლრდ.
Operating income
3,18 მლრდ.
3,51 მლრდ.
3,43 მლრდ.
2,80 მლრდ.
Other non operating income
335,70 მლნ.
321,20 მლნ.
-1,09 მლრდ.
437,60 მლნ.
EBT including unusual items
3,54 მლრდ.
4,00 მლრდ.
3,73 მლრდ.
3,22 მლრდ.
EBT excluding unusual items
3,51 მლრდ.
3,82 მლრდ.
2,94 მლრდ.
3,22 მლრდ.
Income tax expense
965,10 მლნ.
1,04 მლრდ.
952,41 მლნ.
852,70 მლნ.
Effective tax rate
27,26%
26,08%
25,53%
26,44%
Other operating expenses
1,51 მლრდ.
1,54 მლრდ.
-236,82 მლნ.
1,56 მლრდ.
Net income
2,57 მლრდ.
2,96 მლრდ.
2,78 მლრდ.
2,37 მლრდ.
Net profit margin
26,28%
28,39%
27,92%
25,27%
Earnings per share
-
-
-
14,00
Interest and investment income
-
-
657,30 მლნ.
-
Interest expense
-5,10 მლნ.
-11,90 მლნ.
-6,12 მლნ.
-9,70 მლნ.
Net interest expenses
-5,10 მლნ.
-11,90 მლნ.
651,18 მლნ.
-9,70 მლნ.
Depreciation and amortization charges
174,30 მლნ.
203,20 მლნ.
131,74 მლნ.
158,40 მლნ.
EBITDA
3,35 მლრდ.
3,61 მლრდ.
3,52 მლრდ.
2,89 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები